Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cynata Therapeutics Limited ( (AU:CYP) ) has shared an announcement.
Cynata Therapeutics announced a positive review by an independent Data and Safety Monitoring Board (DSMB) for the first cohort in their Phase 1/2 kidney transplant trial using CYP-001, a Cymerus™ MSC therapy. The trial, managed by Leiden University Medical Centre, aims to establish CYP-001 as a safer alternative to current anti-rejection drugs, which have significant toxicity. The DSMB found no safety concerns, allowing the trial to proceed to the next cohort, potentially positioning Cynata as a leader in safer kidney transplantation therapies.
More about Cynata Therapeutics Limited
Cynata Therapeutics Limited is an Australian clinical-stage biotechnology company specializing in stem cell and regenerative medicine. The company focuses on developing therapies based on its proprietary Cymerus™ platform, which uses induced pluripotent stem cells (iPSCs) to produce mesenchymal stem cells (MSCs) economically and at a commercial scale. Cynata’s product candidates include CYP-001 and CYP-006TK, which have shown positive safety and efficacy in clinical trials for conditions like graft versus host disease and diabetic foot ulcers.
Average Trading Volume: 221,989
Technical Sentiment Signal: Buy
Current Market Cap: A$61.74M
Learn more about CYP stock on TipRanks’ Stock Analysis page.